ECCMID data reinforces AstraZeneca's commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies

AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology

Related Keywords

Israel ,India ,Italy ,Japan ,Brazil ,Cambridge ,Cambridgeshire ,United Kingdom ,China ,United States ,Italian ,Brazilian ,Iskra Reic ,Vaxzevria Chadox ,European Medicines Agency Ema Priority ,Japan Agency For Medical Research ,Drug Administration ,University Of Oxford ,Vanderbilt University Medical Center ,Regulatory Agency ,Alliance Revenue ,Serum Institute Of India ,Company On Twitter Astrazeneca ,European Commission ,National Medical Products Administration ,European Congress ,Nasdaq ,Astrazeneca ,Sanofi Alliance ,China Center ,Us Veterans Affairs ,Immune Therapies ,Clinical Microbiology ,Infectious Diseases ,Executive Vice President ,Respiratory Tract Disease ,Lower Respiratory Tract Infections ,United Kingdom Medicines ,Breakthrough Therapy Designation ,Drug Evaluation ,European Medicines Agency ,Drug Selection ,Promote New Drug Development ,Japan Agency ,Medical Research ,Collaboration Revenue ,Serum Institute ,Rare Diseases ,